DFP 10917

Drug Profile

DFP 10917

Alternative Names: DFP-10917; NS 917

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator Delta-Fly Pharma
  • Class Antineoplastics
  • Mechanism of Action Cell cycle inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute lymphoblastic leukaemia; Acute myeloid leukaemia

Most Recent Events

  • 25 May 2017 DFP 10917 licensed to Nippon Shinyaku in Japan
  • 24 Mar 2017 Delta-Fly Pharma completes a phase I/II trial in Acute myeloid leukaemia and Acute lymphoblastic leukaemia in USA
  • 24 Mar 2017 Delta-Fly Pharma plans a global phase III trial for Acute myeloid leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top